Covishield Gets Approval in India; AstraZeneca-Oxford COVID-19 Vaccine Being Produced by Serum Institute of India, Approved For Emergency Use: Reports

Team Latestly
·2-min read

New Delhi, January 1: The COVID-19 Vaccine developed by drug maker AstraZeneca and University of Oxford became the first vaccine to get approval for emergency use in India on Friday. According to the reports, Covishield has been shown green signal by the expert panel of Central Drugs Standard Control Organisation for emergency use. AstraZeneca-Oxford COVID-19 Vaccine Approved for Use in UK, Regulatory Approval in India Awaited.

Also Read | India Initiates Talks With Chinese Authorities to Rescue 39 Indian Sailors Stranded on Board MV Jag Anand And MV Anastasia in Chinese Waters

Despite the approval for emergency use, the Drugs Controller General of India (DCGI) will take a final call on the matter. In India, the Pune-based Serum Institute is manufacturing the AstaZeneca-Oxford COVID-19 vaccine. The vaccine is claimed to be 95 per cent efficient against the coronavirus. Oxford COVID-19 Vaccine's Efficacy Rate Will be 'Around 95%', Claims AstraZeneca CEO Ahead of Likely Rollout in UK and India.

The SEC on COVID-19 had earlier sought additional safety and immunogenicity data from SII, deliberated on its application seeking emergency use authorisation (EUA) for the shots on Wednesday.

Also Read | AstraZeneca-Oxford COVID-19 Vaccine gets Approval for Emergency Use: Reports| Live Breaking News Headlines Updates on January 1, 2021

Adar Poonwalla, the CEO of the Serum Institute had earlier said, "We have 40-50 million doses of Covishield stockpiled. Once we get regulatory approvals in a few days, it'll be down to the Govt to decide how much they can take and how fast. We will be producing around 300 million doses by July 2021."

Before India, Argentina and the United Kingdom have already given emergency use approval to Covishield- the vaccine developed by AstaZeneca and Oxford University and the rollout process has begun.